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BaCKgRoUND aND aIMS: Progressive familial intrahe-
patic cholestasis (PFIC) 6 has been associated with missense 
but not biallelic nonsense or frameshift mutations in MYO5B, 
 encoding the motor protein myosin Vb (myoVb). This genotype- 
phenotype correlation and the mechanism through which 
MYO5B mutations give rise to PFIC are not understood. 
The aim of this study was to determine whether the loss of 
myoVb or expression of patient-specific myoVb mutants can 
be causally related to defects in canalicular protein localization 
and, if so, through which mechanism.
appRoaCH aND ReSUltS: We demonstrate that the 
cholestasis-associated substitution of the proline at amino acid 
position 600 in the myoVb protein to a leucine (P660L) 
caused the intracellular accumulation of bile canalicular pro-
teins in vesicular compartments. Remarkably, the knockout of 
MYO5B in vitro and in vivo produced no canalicular locali-
zation defects. In contrast, the expression of myoVb mutants 
consisting of only the tail domain phenocopied the effects 
of the Myo5b-P660L mutation. Using additional myoVb and 
rab11a mutants, we demonstrate that motor domain-deficient 
myoVb inhibited the formation of specialized apical recycling 
endosomes and that its disrupting effect on the localiza-
tion of canalicular proteins was dependent on its interaction 
with active rab11a and occurred at the trans-Golgi Network/ 
recycling endosome interface.
CoNClUSIoNS: Our results reveal a mechanism through 
which MYO5B motor domain mutations can cause the mislo-
calization of canalicular proteins in hepatocytes which, unex-
pectedly, does not involve myoVb loss-of-function but, as we 
propose, a rab11a-mediated gain-of-toxic function. The results 
explain why biallelic MYO5B mutations that affect the motor 
domain but not those that eliminate  myoVb  expression are 
associated with PFIC6. (Hepatology 2020;72:213-229).
Hepatocytes are polarized epithelial cells with basolateral/sinusoidal plasma membrane domains that is orientated to the blood cir-
culation and apical/canalicular plasma membranes that 
form the bile canaliculi (BC) through which bile is 
safely moved out of the liver. Tight junctions separate 
the sinusoidal and canalicular domains and prevent the 
mixing of bile and blood. Defects in the polarized dis-
tribution or function of cell surface proteins can cause 
severe liver diseases.(1) Of these, progressive familial 
Abbreviations: ANO, anoctamin; ATP8B1, adenosine triphosphatase phospholipid transporting 8b1; BC, bile canaliculi; CRISPR, clustered 
regularly interspaced short palindromic repeat; EGFP, enhanced green fluorescent protein; HEK, human embryonic kidney; hiHep, human-induced 
hepatocyte; KO, knockout; Mrp, multidrug resistance-associated protein; MVID, microvillus inclusion disease; Myc, myelocytomatosis; myoVb, myosin 
Vb; PFIC, progressive familial intrahepatic cholestasis; SDS, sodium dodecyl sulfate; TGN, trans-Golgi Network; TPN, total parenteral nutrition.
Received April 15, 2019; accepted October 17, 2019.
Additional Supporting Information may be found at onlinelibrary.wiley.com/doi/10.1002/hep.31002/suppinfo.
Supported by grants from the Nederlandse vereniging voor Gastroenterologie (to S. I. J.) and the Natural Science Foundation of China, Nos. 
81873543 and 81570468 (to J. S. W.).
© 2019 The Authors. Hepatology published by Wiley Periodicals, Inc., on behalf of American Association for the Study of Liver Diseases. This is 
an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution 
in any medium, provided the original work is properly cited, the use is non-commercial and no modif ications or adaptations are made.
View this article online at wileyonlinelibrary.com.
DOI 10.1002/hep.31002
Potential conflict of interest: Nothing to report.
Hepatology, July 2020OVEREEM ET AL.
214
intrahepatic cholestasis (PFIC) is characterized by the 
inability of hepatocytes to secrete bile into the cana-
liculi, resulting in the buildup of bile components and 
liver failure. PFIC can be caused by mutations in differ-
ent genes,(2) including adenosine triphosphatase phos-
pholipid transporting 8B1 (ATP8B1); PFIC1), ATP 
Binding Cassette Subfamily B Member 11 (ABCB11) 
(PFIC2), ATP Binding Cassette Subfamily B Member 
4 (ABCB4) (PFIC3), tight junction protein 2 (TJP2) 
(PFIC4), and nuclear receptor subfamily 1, group H, 
member 4 (NR1H4; PFIC5). ATP8B1, ABCB11, and 
ABCB4 encode canalicular membrane transporters. 
Mutations in these proteins affect their expression, 
canalicular localization, or function and consequently 
impair bile salt secretion (ABCB11/bile salt export 
pump [BSEP]) or phospholipid dynamics in the can-
alicular membrane (ATP8B1, multidrug resistance 
protein 3). NR1H4 encodes the farnesoid X receptor, 
a transcription factor that regulates the expression of 
ABCB11/BSEP. TJP2 encodes the tight junction pro-
tein zona occludens-2, and mutations in these presum-
ably lead to the leaking of bile out of the canaliculi.
Recently, mutations in the MYO5B gene were 
reported in a group of patients with PFIC who pre-
sented elevated bilirubin and bile acid levels with 
normal gamma-glutamyl transpeptidase (GGT) lev-
els and did not have mutations in any of the other 
PFIC genes.(3,4) Unique MYO5B mutations were 
associated with each affected family. MYO5B encodes 
the actin-filament–based motor protein myosin Vb 
(myoVb). MyoVb binds selected small guanosine 
triphosphatase (GTPase) rab proteins, including the 
trans-Golgi Network (TGN)-associated and/or recy-
cling endosome-associated rab8 and rab11a, and has 
been implicated in apical plasma membrane protein 
trafficking. Mutations in MYO5B can also cause 
microvillus inclusion disease (MVID),(5-8) a congen-
ital enteropathy characterized by intractable diarrhea 
and malabsorption and, at the cellular level, the mis-
localization of apical brush border proteins. Notably, 
many—but not all—patients with MVID also develop 
cholestasis, leading to liver failure.(9)
How MYO5B mutations may lead to PFIC is not 
known. Given the effect of MYO5B mutations on the 
apical localization of brush border proteins in enterocytes 
in MVID, it is possible that myoVb is similarly needed 
for the correct localization of BC proteins in hepato-
cytes and can cause cholestasis when mutated. In vitro 
studies in the hepatic WIF-B9 cell line, in which the 
ectopic expression of a rat myoVb tail fragment impaired 
canalicular protein trafficking,(10) may support this 
hypothesis. In situ studies, however, showing no immu-
nohistochemical abnormalities of canalicular transporters 
in liver biopsies of some patients with MYO5B muta-
tions presenting severe cholestasis,(3,11) challenge this 
hypothesis. Furthermore, although missense, nonsense, 
and frameshift MYO5B mutations all have been associ-
ated with MVID (reviewed in van der Velde et al.(7)), 
biallelic nonsense and frameshift mutations predicted 
to eliminate myoVb expression are noticeably absent in 
patients with non-MVID cholestasis.(3,12) Thus, not all 
pathogenic MYO5B mutations may lead to PFIC and/or 
canalicular protein localization defects.
Notably, causality between patient MYO5B muta-
tions and the mislocalization of BC proteins in hepato-
cytes has not been experimentally addressed. The need 
to decisively determine whether a causal relationship 
exists between patient-specific MYO5B mutations and 
canalicular protein localization defects is particularly 
relevant for PFIC presenting in patients with MVID. 
Indeed, because patients with MVID receive lifelong 
total parenteral nutrition (TPN), which itself may 
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induce cholestasis and liver failure,(13,14) it is difficult 
to determine whether liver symptoms in these patients 
are MYO5B mutation or TPN induced.
The aim of this study was to address the causal rela-
tionship between patient MYO5B mutations and cana-
licular protein mislocalization and to clarify the PFIC 
disease mechanism in these patients. We demonstrate 
that myoVb is dispensable for the correct localization of 
BC proteins yet can cause cholestasis-associated defects 
in their localization when mutated through an unex-
pected mechanism involving the small GTPase rab11a.
Materials and Methods
Cell CUltURe
HepG2 cells (American Type Culture Collection 
HB8065) were maintained in high-glucose Dulbecco’s 
modified Eagle’s medium with 10% heat-inactivated 
fetal bovine serum, 2  mM l-glutamine, 100  IU/mL 
penicillin, and 100 μg/mL streptomycin in a humid-
ified atmosphere. For experiments, cells were plated 
on poly-L-lysine–coated coverslips and used 3  days 
later. Human embryonic stem cell line 9 (HUES9) 
cells were maintained on vitronectin in E8 (Thermo 
Fisher). Cells were passaged every 4-5 days with 1% 
RevitaCell Supplement added to the cells overnight 
on day of passage. Differentiation of HUES9 cells to 
hepatocytes was as described.(15)
VIRal tRaNSDUCtIoN
Lentiviral particles were produced using a sec-
ond-generation system based on pCMVdR8.1 and 
pVSV-G. Human embryonic kidney (HEK) 293T cells 
in the amount of 1 × 106 were transferred to poly-L-
lysine–coated 9 cm2 plates in 1.3 mL culture medium. 
Lentiviral vector in the amount of 1,200 ng, 1,000 ng 
pCMVdR8.1, and 400  ng pVSV-G were mixed with 
7.8  μL FuGENE HD in 200  μL Opti-MEM and 
added to suspension HEK293T. After overnight incu-
bation, medium was refreshed, and after 48 hours, viral 
particles were harvested and filtered (0.45 μm polyvi-
nylidene fluoride [PVDF] membrane filter). One day 
after plating, cells were incubated with viral particles 
for 16 hours (supplemented with 8 μg/mL polybrene). 
Antibiotics (2.5 μg/mL puromycin, 4 μg/mL blastici-
din) were added 24 hours after viral incubation.
ClUSteReD RegUlaRly 
INteRSpaCeD SHoRt 
palINDRoMIC Repeat 
KNoCKoUt
A lentiviral clustered regularly interspaced short pal-
indromic repeat (CRISPR) construct targeting Exon3 
of MYO5B was generated using the plentiCRISPR-V2 
vector (Addgene #52961) following provided protocols 
(guide RNA target sequence: tcttacggaatccagatatc). 
Cells were transduced and selected with puromycin 
as described. Cells were plated on poly-L-lysine coat-
ing at 18 cells/cm2 with untreated cells/cm2 as feeder 
layer. After 4 days, cells were selected with puromycin 
(2.5 μg/mL) to kill feeder cells, and remaining colonies 
were isolated as separate lines. To deplete MyoVb in 
HUES9 cells, the cells were incubated with MYO5B-
targeting lentiCRISPR viral supernatant for 5 hours 
(in E8 medium supplemented with 8  μg/mL poly-
brene). After 48 hours, cells were selected with puro-
mycin (1  μg/mL). Selected cells were then plated at 
28 cells/cm2, and the resulting colonies were mechan-
ically passaged after 3 weeks. Clones were checked for 
myoVb knockout (KO) by means of a western blot.
plaSMIDS
Full-length human myoVb-coding sequence was 
amplified from HepG2 complementary DNA (cDNA) 
through PCR, including a myelocytomatosis (myc)- 
encoding ‘5 overhang in the forward primer sequence. 
Amplified myc-myoVb was inserted into pENTR1a 
vectors. All described myoVb mutants were generated by 
modification of this construct using the Q5 Site-Directed 
Mutagenesis Kit (New England BioLabs) with primers 
designed in the NEBaseChanger tool. MyoVb and thereof 
derived mutant constructs were transferred to lentiviral 
vectors for mammalian expression through Gateway clon-
ing using LR Clonase II (Thermo Scientific) as per man-
ufacturer’s instruction. Full-length myc-myoVb constructs 
were transferred to pLenti-cytomegalovirus (CMV)-
Blast-DEST (706-1; Addgene #17451), and myc-myoVb 
tail domain constructs to pLenti-CMV-Puro-DEST 
(w118-1; Addgene #17452). Enhanced green fluores-
cent protein (EGFP)-tagged wild type (WT) rab11a 
(rab11aWT) and the EGFP-tagged dominant negative 
mutant of rab11a in which the serine at position 25 is 
subsitituted with an asparagine (rab11aS25N)(16) were 
gifts from R.E. Pagano (Mayo Clinic).
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WeSteRN BlottINg
Cells were resuspended in radio immunoprecipita-
tion assay buffer (150  mM NaCl, 1% Nonidet P40, 
0.5% sodium deoxycholate, 0.1% sodium dodecyl sul-
fate (SDS), 50  mM Tris pH 8.0) containing prote-
ase inhibitors. Lysates were mixed with sample buffer 
(2% SDS, 5% β-mercaptoethanol, 0.125M Tris–HCl, 
pH 6.8, 40% glycerol, 0.01% bromophenol blue) and 
incubated at 70°C for 10  minutes. Samples were 
resolved with SDS-polyacrylamide gel electrophore-
sis and electro-transferred onto PVDF membranes. 
Membranes were blocked with Odyssey-blocking buf-
fer and incubated overnight at 4°C with primary anti-
bodies (Supporting Table S1). After incubation with 
secondary antibodies, immunoblots were scanned with 
the Odyssey (LI-COR Biosciences). Relative quanti-
fication was performed using the Odyssey software.
MICRoSCopy
Immunolabeling and fluorescence microscopy were 
performed essentially as described.(3,8) Antibodies used 
are listed in Supporting Table S1. Fluorescent mul-
tiplex immunohistochemistry of paraffin-embedded 
liver tissue of a reported patient with PFIC6(3) and 
an anonymous donor with cholangitis as control was 
performed with standard procedure of Tyramine Signal 
Amplification. Fluorescent images were analyzed using 
a combination of ImageJ and Adobe Photoshop. For 
electron microscopy, cells were fixed by adding drop-
wise an equal volume fixative (2% glutaraldehyde and 
2% paraformaldehyde in 0.1  M sodium cacodylate 
buffer). After 10 minutes, this mixture was replaced by 
pure fixative at room temperature for 30 minutes. After 
fixation in 1% osmium tetroxide/1.5% potassium ferro-
cyanide (4°C; 30 minutes), cells were dehydrated using 
ethanol and embedded in EPON epoxy resin. Then, 
60-nm sections were cut and contrasted using 2% ura-
nyl acetate followed by Reynolds lead citrate. Images 
were captured with a Zeiss Supra 55 in scanning and 
transmission electron microscopy mode at 26 KV.
Real-tIMe QUaNtItatIVe pCR
RNA was harvested using trizol reagent (Sigma). 
RNA was reverse transcribed in the presence of oli-
go(dT)12-18 (Invitrogen) and deoxyribonucleotide 
triphosphate (Invitrogen) with Moloney murine leu-
kemia virus reverse transcriptase (Invitrogen). Gene 
expression levels were measured by real-time quanti-
tative RT-PCR using ABsolute aPCR SYBR Green 
Master Mix (Westburg) in a Step-One Plus Real-
Time PCR machine (Applied Biosystems), and the 
resulting data were analyzed using the LinRegPCR 
method. The primers used to mutate MYO5B cDNA 
were as follows:
Forward -ACCAGCTGCCgTTCTTACGGA-.
Reverse -TGCGTTGTACATCAATTGGG-.
StatIStICS
For all phenotype quantifications, statistical signif-
icance of differences between triplicate experiments 
was determined using Student t test (two-tailed, 
unpaired, equal variance). Replicates represent quanti-
fications of >200 cells. P values: *P < 0.05, **P < 0.01, 
***P < 0.001.
Results
MyoVb DeFICIeNCy DoeS Not 
DISRUpt CaNalICUlaR pRoteIN 
loCalIZatIoN
Displacement of BC transporters to the cyto-
plasm of hepatocytes has been shown in liver biopsies 
of patients with MVID presenting with cholestasis 
and homozygous missense mutations (c.1979C>T/p.
P660L)(17) and a patient with non-MVID PFIC 
with homozygous missense mutations (c.796T>C/p.
C266R)(3) in the MYO5B gene. Here, we demonstrate 
the mislocalization of BC transporters to intracellular 
compartments in hepatocytes of an additional patient 
with non-MVID PFIC6 carrying a missense MYO5B 
mutation (c.437C>T/p.S158F(3); Supporting Fig. S1), 
thereby expanding the number of patients with 
PFIC in which missense MYO5B mutations correlate 
with a cytoplasmic displacement of BC transport-
ers. Intriguingly, in patients with cholestatic MVID 
with nonsense MYO5B mutations, a normal local-
ization of BC transporters was reported,(11) suggest-
ing that loss of myoVb expression is not sufficient to 
induce BC transporter mislocalization. To address the 
requirement of MYO5B expression for the localization 
of BC transporters in hepatocytes, we examined the 
in vivo distribution of the ATP-binding  cassette 
sub-family C member 2 (ABCC2)/multidrug 
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resistance-associated protein (Mrp) 2 and the structural 
BC protein radixin in the liver of whole-body Myo5b 
KO mice.(18) We observed their exclusive localization 
at BC, indistinguishable from wild-type control mouse 
livers (Fig. 1A,B). Human HepG2 cells (HepG2Par) 
develop apical-basolateral polarity and BC lumens 
between adjacent cells.(19) In agreement with the obser-
vations in Myo5b KO mouse hepatocytes, HepG2 cells 
FIg. 1. MyoVb deficiency does not disrupt canalicular protein localization. (A,B) Immunofluorescent staining of ABCC2 and radixin 
reveals their canalicular localization in both wild-type and Myo5b KO mouse liver sections. HNF4α costaining marks hepatocytes. (C) KO 
of MYO5B in HepG2KO cells (treated with MYO5B-targeting pLentiCRISPR V2) was confirmed by western blot (compared with parental 
line, HepG2PAR). (D) In HepG2 cells, localization of ABCC2 and F-actin is unaffected by MYO5B KO (HepG2KO) compared with 
HepG2PAR control. Yellow arrowheads indicate BCs. (E) Western blot for myoVb in HUES9KO cells confirmed MYO5B KO (compared 
with parental line, HUES9Par). (F) HiHeps generated from HUES9KO cells exhibit BC formation comparable with HUES9Par-derived 
hiHeps, with exclusive canalicular labeling of ABCC2. Scale bars: 10 μm.
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in which endogenous myoVb had been knocked out by 
CRISPR/CRISPR-associated protein 9 (Cas9; Fig. 1C; 
Supporting Fig. S2A; HepG2KO cells) showed no defect 
in the canalicular localization of ABCC2/MRP2, which 
was indistinguishable from that in HepG2Par cells (Fig. 
1D). Similar results were obtained with another cana-
licular protein, anoctamin (ANO)-6 (Supporting Fig. 
S2B,C). We also generated a myoVb-deficient HUES9 
human pluripotent stem cell line through CRISPR/
Cas9-mediated gene KO (HUES9KO; Fig. 1E) 
and differentiated these to polarized hepatocyte-like 
cells (human-induced hepatocyte [hiHep]). These 
hiHeps form in vivo-like multicellular BC (Fig. 1F).(15) 
Similar to the results in HepG2KO cells, hiHeps derived 
from HUES9KO cells formed multicellular BC to 
which ABCC2/MRP2 exclusively localized, similar to 
HUES9Par-derived hiHeps (Fig. 1F).
These data show that missense myoVb mutations 
can correlate with a cytoplasmic displacement of BC 
transporters, whereas myoVb as such is dispensable 
for the correct localization of BC transporters at the 
canalicular membrane.
MVID-aSSoCIateD myoVb-
p660l MUtatIoN CaUSeS 
INtRaCellUlaR aCCUMUlatIoN 
oF CaNalICUlaR pRoteINS
Causality between patient MYO5B mutations and 
the mislocalization of BC proteins in hepatocytes has 
not been experimentally addressed. Investigation of 
such causality is particularly relevant for PFIC pre-
senting in patients with MVID, as their long-term 
parenteral nutrition obscures the etiology of hepatic 
dysfunction. We therefore focused on the founding 
homozygous c.1979C>T mutation in the MYO5B 
gene of Navajo patients with MVID.(6) These patients 
display liver disease, and liver biopsies from these 
patients have been shown to display cytoplasmic dis-
placement of canalicular bile acid transporters and 
signs of perturbed polarity.(17)
To determine whether this MYO5B mutation, 
leading to a P660L substitution in the myoVb pro-
tein, could be causally linked to canalicular protein 
localization defects, a full-length human myc-tagged 
MYO5B gene with the c.1979C>T mutation was con-
structed through site-directed mutagenesis, and either 
the myc-tagged wild-type myoVb or myc-myoVb-
P660L protein was expressed in HepG2KO cells. The 
expression of myoVb-P660L in HepG2KO cells caused 
the intracellular accumulation of the BC proteins 
ABCC2/MRP2 and ANO6, when compared with 
HepG2KO cells expressing the wild-type MYO5B gene 
(Fig. 2A-C). This was accompanied by a reduction in 
the amount of BC (Supporting Fig. S2D). Notably, 
HepG2Par cells that expressed myoVb-P660L showed 
a less severe phenotype (more BCs with subapical 
localization of the mutant protein and less intracellu-
lar accumulation of the mutant protein and canalicu-
lar proteins) when compared with HepG2KO cells that 
expressed myoVb-P660L (Supporting Fig. S2E-H, cf. 
Fig. 2). These data demonstrate that in the absence 
of wild-type myoVb, mutant myoVb-P660L caused 
the intracellular accumulation of BC-resident proteins 
and provide evidence that this mutation is causally 
linked to the hepatic canalicular defects as observed 
in liver biopsies of the patients. Moreover, given the 
absence of a localization defect in myoVb-depleted 
cells, the results also indicate that the disruptive effect 
of myoVb-P660L on the localization of canalicular 
proteins in hepatocytes cannot be explained by the 
mere loss of myoVb function.
taIl DoMaIN oF myoVb 
IS SUFFICIeNt to CaUSe 
INtRaCellUlaR aCCUMUlatIoN 
oF VeSICleS aND BC pRoteINS
Because the mutated motor domain but not the 
absence of the myoVb protein produced a disease 
phenotype, we hypothesized that regions that were 
distal to the motor domain (IQ domains, coiled-coil 
domains, and/or the globular tail domain) may have 
been instrumental to the disruptive effects on the 
localization of canalicular proteins. Therefore, we 
generated a human myoVb mutant that lacked the 
motor domain, IQ domains, and part of the coiled-
coil domain (Fig. 3A), which is similar to conven-
tionally used dominant-negative myoVb tail domain 
constructs (hereafter referred to as myoVb/Δ1-1195). 
Similar to myoVb-P660L, the expression of myoVb/
Δ1-1195 in HepG2KO cells resulted in the intracel-
lular accumulation of ABCC2/MRP2 and ANO6 
and a reduction in the number of BCs (Supporting 
Fig. S3A-E). Notably, the effect of myoVb/Δ1-1195 
was more severe when compared with myoVb-P660L 
and was also observed when expressed in HepG2Par 
cells (Fig. 3B-E, Supporting Fig. S4A). Also, the 
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FIg. 2. The MVID-associated myoVb-P660L mutation causes the intracellular accumulation of canalicular proteins. (A,B) 
Immunofluorescent microscopy images of myc-tagged myoVb proteins, ABCC2 and ANO6, in HepG2KO expressing myc-myoVb and 
myc-myoVb-P660L. HepG2KO cells expressing myoVb-P660L show intracellular colocalization of myc and ABCC2 (white arrows). 
Yellow arrowheads indicate BCs. Scale bars: 10 μm. (C) Quantification of the percentage of myc-positive cells that show intracellular 
clusters/accumulations of myc localized with ANO6. (D) Quantification of the percentage of myc-positive cells that show subapical 
localization of myc-tagged myoVb proteins.
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FIg. 3. The tail domain of myoVb is sufficient to cause the intracellular accumulation of vesicles and BC proteins. (A) Schematic 
depiction of myoVb constructs. (B) Labeling of ANO6 and myc in HepG2Par cells expressing myc-myoVb/Δ1-1195 (white arrows 
indicate intracellular colocalization of both markers). (C) Quantification of the percentage of HepG2Par cells showing accumulation of 
ABCC2 (as shown in Fig. 4C) on expression of myc-myoVb/Δ1-1195 compared with untreated cells and cells transduced with an empty 
pLenti-Puro construct (control). (D,E) Labeling of ABCC2 and F-actin or ANO6 in HepG2Par cells expressing myc-myoVb/Δ1-1195 
compared with untreated control. White arrows indicate intracellular accumulation of ABCC2 (and ANO6 in Fig. D). Scale bars: 10 μm 
unless labeled otherwise. Yellow arrowheads indicate BC. (F) Electron microscopy images of HepG2Par cells expressing myc-myoVb/Δ1-
1195. Cells displayed large collections of vesicles (enlarged areas) that were not observed in control cells.
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canalicular protein dipeptidyl peptidase IV accumu-
lated inside the cells (Supporting Fig. S4B,C). The 
myoVb/Δ1-1195 mutant itself colocalized with the 
intracellular clusters (Fig. 3B). Electron microscopy of 
HepG2 cells expressing the myoVb mutant revealed 
the presence of large clusters of vesicles, which were 
not observed in control HepG2 cells (Fig. 3F). Finally, 
the expression of myoVb/Δ1-1195 in pluripotent 
HUESPar stem cell–derived hepatocytes also caused 
the intracellular accumulation of ABCC2/MRP2 and 
ANO6 (Fig. S4D), which indicated that the effects 
caused by this mutant are not specific for the HepG2 
cell line. Together, these results indicate that, in con-
trast to the loss of myoVb, the expression of the tail 
domain of myoVb mimicked the myoVb-P660L–
induced intracellular accumulation of BC proteins.
MotoRleSS myoVb INDUCeS 
aCCUMUlatIoN oF apICal aND 
BaSolateRal pRoteINS IN 
ClUSteReD CoMpaRtMeNtS 
WItH MIXeD ReCyClINg 
eNDoSoMe aND tgN IDeNtIty
The intracellular clusters of BC proteins and the 
appearance of clusters of vesicles in myoVb mutant- 
expressing cells suggested that these clusters rep-
resented intracellular organelles. To determine the 
identity of the mutant myoVb-induced ABCC2/
MRP2- and ANO6-containing intracellular clusters, 
we performed immunofluorescence microscopy in 
cells colabeled with markers for different organelles. 
Proteins that make up BC microvilli, such as F-actin, 
the ABCC2/MRP2- and F-actin–binding pro-
tein radixin, or other phosphorylated proteins of the 
ezrin-radixin-moesi (ERM) family, did not colocalize 
with the BC protein–containing intracellular cluster in 
cells expressing myoVb/Δ1-1195 (Fig. 4A, Supporting 
Fig. S5A), indicating that these clusters did not repre-
sent microvillus inclusions, which represent a hallmark 
of enterocytes in patients with MVID.(20)
By contrast, intracellular clusters containing BC 
proteins colocalized with the apical recycling endo-
some markers rab11a and its interacting protein 
rab11a-family of interacting proteins number 5/rab- 
interacting protein (rip11; Fig. 4B,C). This subcellular 
distribution of rab11a and its rip11 was markedly 
distinct from their exclusive subapical distribution in 
HepG2 cells that did not express the mutant protein. 
However, the subcellular distribution of rab11a and 
rip11 in HepG2KO cells and HepG2Par cells was indis-
tinguishable, supporting the idea that myoVb expres-
sion is dispensable for canalicular polarity (Supporting 
Fig. S5B,C). Also, the recycling endosome-associated 
rab8, which in control HepG2 cells showed a rela-
tively dispersed cytoplasmic staining pattern, colocal-
ized with the clusters in cells expressing the myoVb 
mutants (Fig. 4D). Lysosomal-associated membrane 
protein 1, a marker of late endosomes/lysosomes, did 
not colocalize with the canalicular protein–containing 
clusters, and its subcellular distribution pattern was 
not visibly altered (Supporting Fig. S5D). In addition 
to BC proteins, the sinusoidal transferrin receptor 
and its ligand transferrin, which upon its endocyto-
sis is recycled to the sinusoidal surface through recy-
cling endosomes, was found to colocalize with the BC 
protein–containing clusters (Fig. 4E, Supporting Fig. 
S5E). Moreover, when fluorescently labeled transfer-
rin was allowed to be endocytosed in control HepG2 
cells or HepG2 cells expressing mutant myoVb, its 
subsequent recycling to the cell surface was inhibited 
in cells expressing the myoVb mutant, as evidenced by 
its persistent accumulation in the ANO6- and trans-
ferrin receptor-containing clusters (Fig. 4E).
Although the cis-Golgi protein giantin did not 
colocalize with the BC protein–containing clusters 
(Fig. 5A), we found that three markers of the TGN 
partly colocalized with the BC protein–containing 
clusters (Fig. 5B-D). These included TGN46 and 
golgin-97. With the exception of AP1y, which, in 
addition to its typical TGN-like distribution pat-
tern, was also observed in the subapical region of 
control HepG2 cells, TGN46 and golgin-97 did not 
show a subapical localization in control HepG2 cells 
(Fig. 5B-D). Together, these results indicate that the 
BC protein–containing clusters in cells expressing the 
myoVb mutant represented trafficking-incompetent 
compartments with a mixed apical recycling endo-
some and TGN identity.
DISRUptINg effect oF 
MotoRleSS myoVb oN 
CaNalICUlaR pRoteIN 
loCalIZatIoN ReQUIReS 
aCtIVe rab11a
We hypothesized that the myoVb tail domain 
induced canalicular defects through rab8 or rab11a 
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FIg. 4. Motorless myoVb induces the accumulation of apical and basolateral proteins in clustered compartments that display recycling 
endosome identity. (A) Phospho-proteins of the ezrin-radixin-moesi (ERM) family are not present in myc-myoVb/Δ1-1195 clusters 
(white arrows). Yellow arrowheads indicate BC. (B-D) Labeling of rip11, rab11a, and rab8 with ANO6 or ABCC2 in HepG2 expressing 
myc-myoVb/Δ1-1195 (white arrows) compared with control. White arrows indicate colocalization of endosomal proteins with BC-
resident protein. The yellow arrowhead indicates juxta-nuclear staining of rip11 in nonpolarized control cells. (E) Labeling of myc in 
control and myc-myoVb/Δ1-1195 expressing HepG2, fixed after 30 minutes incubation (t = 0 hours) with fluorescently labeled transferrin 
(388Tf ) and after a 2-hour chase period. 488-Transferrin localized with myc-myoVb/Δ1-1195 clusters (white arrows) at t = 0 hours and 
at t = 2 hours. Scale bars: 10 μm.
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FIg. 5. Motorless myoVb induces the accumulation of apical and basolateral proteins in clustered compartments that also display TGN 
identity. (A) Giantin labeling in HepG2 cells expressing myc-myoVb/Δ1-1195 compared with control. White arrows indicate lack of 
colocalization. (B,C) Golgin-97 and TGN46 showed colocalization with intracellular cluster of ANO6 in HepG2 expressing myc-
myoVb/Δ1-1195 (white arrows). (D) AP1y localized with ANO6 in intracellular clusters in HepG2 expressing myc-myoVb/Δ1-1195 
(white arrows). Scale bars: 10 μm.
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function rather than competition with endogenous 
myoVb. To test whether the observed defects are medi-
ated through rab8 or rab11a, we generated a myoVb 
mutant, which comprised only the globular tail domain 
(the last 383 amino acids) and did not contain the 
binding site for rab8 in ExonC/Exon30 (referred to 
as myoVb/Δ1-1460; Fig. 6A). Like myoVb/Δ1-1195, 
myoVb/Δ1-1460 mutant led to the intracellular accu-
mulation of BC proteins and a reduction in the num-
ber of BCs, albeit to a lesser extent than the myoVb/
Δ1-1195 mutant, suggesting that rab8 binding may 
contribute but is not essential to induce the effect 
(Fig. 6B,C, Supporting Fig. S5A). Indeed, substitu-
tion of glycine at position 1300 in myoVb/Δ1-1195 to 
a leucine, a mutation known to abolish the interaction 
between myoVb and rab8,(21) partially ameliorated its 
disrupting effects to the levels seen with the myoVb/
Δ1-1460 mutant (Fig. 6B,D). By contrast, when tyro-
sine at position 1714 in myoVb/Δ1-1460 was mutated 
to glutamic acid (Y1714E; Fig. 6E-G), a mutation 
that abolishes myoVb binding to rab11a,(21) the intra-
cellular accumulation of the canalicular proteins was 
completely abolished. Similarly, the introduction of 
this Y1714E mutation in the patient myoVb-P660L 
mutant reduced the intracellular accumulation of the 
canalicular proteins (Fig. 7A-C). Notably, the intro-
duction of Y1714E in myoVb/Δ1-1460 or myoVb-
P660L did not lead to an increase in the number 
of BC.
Moreover, the myoVb/Δ1-1195 mutant, as well 
as the patient myoVb-P660L mutant, failed to cause 
the intracellular clustering of ABCC2/MRP2 when 
expressed in HepG2 cells that also expressed the 
EGFP-tagged mutant rab11aS25N (Fig. 7D), which is 
expected to shift the equilibrium of rab11a toward the 
guanosine diphosphate/nucleotide-free state and exert 
dominant-negative effects on endogenous rab11a by 
occupying the endogenous guanine nucleotide exchange 
factors (GEFs). Consistent with reports in other cells(22) 
and the previously reported location of two rab11 
GEFS, rab11-interacting protein-1, and Crag at the 
TGN, EGFP-rab11aS25N colocalized with the TGN 
in HepG2 cells (Fig. 7E). Although the expression of 
EGFP-tagged mutant rab11a-S25N in HepG2 cells, as 
such, inhibited polarity development, it did not cause 
the intracellular clustering of BC proteins (Fig. 7F-H). 
Cells expressing wild-type EGFP-rab11a showed nor-
mal BC formation and a subapical distribution of the 
EGFP-rab11a, similar to wild-type cells (Fig. 7F-G). 
Thus, the intracellular clustering of BC proteins in cells 
expressing myoVb-P660L or the myoVb tail domain is 
not phenocopied by loss of rab11a function. Together, 
we conclude that the interaction of the myoVb-P660L 
or myoVb/Δ1-1195 mutant with active rab11a is 
required for the myoVb-P660L- or myoVb/Δ1-1195–
induced intracellular accumulation of BC proteins, but 
not inhibition of polarity development, and that loss of 
rab11a function inhibited polarity development inde-
pendent of myoVb.
MVID-aSSoCIateD NoNSeNSe 
MYO5B MUtatIoNS pRoDUCINg 
tRUNCateD myoVb MUtaNtS 
Do Not DISRUpt HepatoCyte 
polaRIty aND CaNalICUlaR 
pRoteIN loCalIZatIoN
We reasoned that if the disrupting effect of 
motor-deficient myoVb mutants on the localization 
of canalicular proteins required their interaction with 
rab11a through the distal C-terminal binding Y1714 
residue, nonsense MYO5B mutations that cause a pre-
mature translation termination codon and the resul-
tant synthesis of truncated myoVb proteins should 
not lead to polarity defects. We therefore generated 
different MYO5B nonsense mutations previously 
reported in patients with MVID and listed in the 
MVID registry (www.mvid-centr al.org), myoVb-
R363X (c.1087C>T), myoVb-R1016X (c.5382C>T), 
and myoVb-R1795X (c.5383C>T; Fig. 8A), and 
expressed these in HepG2KO cells. Note that in con-
trast to the myoVb-R363X and myoVb-R1016X 
mutants the myoVb-R1795X mutant contains the 
rab11a-binding site. Western blot analyses confirmed 
that these mutants led to the expression of truncated 
myoVb proteins at their predicted molecular weights 
(Fig. 8B). Fluorescence microscopy showed that the 
mutants failed to cause the intracellular accumulation 
of ABCC2/MRP2 (Fig. 8C). These results demon-
strate that nonsense MVID–associated MYO5B muta-
tions and the expression of resultant truncated myoVb 
mutants that lack the globular tail domain do not 
cause defects in BC formation and canalicular protein 
localization, and they support our observations that 
the C-terminal region and a conserved interaction 
with rab11a is required for myoVb mutants to disrupt 
the localization of canalicular proteins.
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FIg. 6. The role of rab8 and rab11a binding sites in the disrupting effect of motorless myoVb on canalicular protein localization. (A) 
Schematic depiction of the amino acid sequences of myoVb mutants. (B) Quantification of the percentage of HepG2 cells showing 
intracellular accumulation of ABCC2 on expression of myoVb tail domain mutants. (C) HepG2 cells expressing myc-myoVb/Δ1-
1460 showed intracellular ABCC2 accumulation (white arrows). Myc labeling showed myc-myoVb/Δ1-1460 localized diffusely in the 
cytoplasm. (D) Labeling of ABCC2, F-actin, and myc in HepG2 expressing myc-myoVb/Δ1-1195-Q1300L and untreated control. White 
arrows indicate intracellular ABCC2 accumulation. (E) In HepG2 cells expressing myc-myoVb/Δ1-1460-Y1714E ABCC2 localized at 
the BC with F-actin (yellow arrowheads). Labeling for myc confirmed expression of the construct. (F) Quantification of the percentage 
of cells with intracellular multidrug resistance protein (MDR) 1-GFP accumulations (depicted in Fig. 8G), on expression of myc-myoVb/
Δ1-1460 or its Y1714E mutant variant. (G) HepG2 cells expressing myc-myoVb/Δ1-1460 showed intracellular accumulation of the 
coexpressed BC marker MDR1-GFP (white arrows) but not when the Y1714E mutation was introduced in myc-myoVb/Δ1-1460.
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FIg. 7. The disrupting effect of motorless myoVb on canalicular protein localization requires active rab11a. (A) ANO6 and myc labeling 
in HepG2KO expressing myc-myoVb-P660L or myc-myoVb-P660L-Y1714E. Myc-myoVb-P660L frequently accumulated intracellularly 
with ANO6 (white arrows), whereas myc-myoVb-P660L-Y1714E appeared diffuse in the cytoplasm or subapical (yellow arrowheads). 
(B) Quantification of the percentage of myc-positive cells that show intracellular clusters/accumulations of myc localized with ANO6 
in HepG2KO cells expressing myc-myoVb-P660L or myc-myoVb-P660L-Y1714E. (C) Quantification of the percentage of myc-
positive cells that show subapical localization of myc in HepG2KO cells expressing myc-myoVb-P660L or myc-myoVb-P660L/Y1714E. 
(D) HepG2 coexpressing EGFP-rab11aS25N and myc-myoVb/Δ1-1195 in HepG2Par cells (left), EGFP-rab11aS25N and myc-myoVb-
P660L in HepG2Par cells (middle), and EGFP-rab11aS25N and myc-myoVb-P660L in HepG2KO HepG2 (right). In all three conditions, 
the presence of EGFP-rab11aS25N prevented the clustering of the respective myoVb mutants. (E) EGFP-rab11aS25N colocalized with 
golgin-97 in HepG2 cells. (F) ABCC2 labeling in HepG2 overexpressing wild-type EGFP-rab11a or EGFP-rab11aS25N. In EGFP-
rab11aS25N transduced cells, BC formation was only seen in cells with no or very low expression of the construct (right side, box). 
(G) Quantification of BC formation (expressed as BC/100 cells) in HepG2 cells expressing wild-type EGFP-rab11a or EGFP-
rab11aS25N. (H) Quantification of the percentage of HepG2 cells showing accumulation of ABCC2 on expression of wild-type EGFP-
rab11a or EGFP-rab11aS25N.
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Discussion
Determination of causality between patient MYO5B 
mutations and mislocalization of BC proteins in 
patients with cholestasis is essential to understand the 
etiology of the disease. In this study, we demonstrated 
that the founding Navajo myoVb-P660L mutant(6) 
when expressed in hepatic HepG2 cells caused the 
aberrant localization of canalicular proteins as well as 
the sinusoidal transferrin receptor to intracellular clus-
ters. These data are in agreement with observations 
in hepatocytes in liver biopsies of patients with this 
mutation and therefore show that the liver symptoms 
and hepatocyte defects observed in Navajo patients 
with MVID(17) are likely a direct consequence of their 
MYO5B mutation rather than a sole consequence of 
intestinal failure–induced or TPN-induced liver dam-
age. The causality between myoVb-P660L and the 
mislocalization of canalicular transporters suggest 
similar mechanisms for PFIC6 in patients carrying 
other missense MYO5B mutations. Although differ-
ent missense mutations may affect the myoVb protein 
differently,(7,12) the clear mislocalization of canalicular 
proteins to intracellular compartments as shown in 
FIg. 8. MVID-associated nonsense MYO5B mutations producing truncated myoVb mutants do not disrupt hepatocyte polarity and 
canalicular protein localization. (A) Schematic depiction of the amino acid sequences of nonsense myoVb mutants. (B) Western blot 
showing the truncated myoVb mutant proteins expressed in HEK293 cells. (C) Immunofluorescence microscopy images showing the 
subcellular distribution of the truncated myoVb mutant proteins and the canalicular protein ABCC2. Scale bars: 10 μm.
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this study for another PFIC6 patient with a different 
missense MYO5B mutation supports this.
Insight into the mechanism through which 
(mutant) myoVb (de)regulates hepatocyte function 
is necessary to understand the pathogenesis of the 
disease. We demonstrated that the loss of myoVb in 
human or mouse hepatocytes, as well as the expression 
of patients’ nonsense MYO5B mutations, did not cause 
the aberrant localization of canalicular proteins, indi-
cating that myoVb function as such is not required 
for the correct localization of BC proteins. Instead, 
the hepatocyte polarity phenotype as observed in 
myoVb-P660L–expressing cells was faithfully phe-
nocopied by the expression of myoVb mutants that 
lacked the entire motor domain and consisted of only 
the tail domains of the myoVb protein.
These results indicated that the effects of myoVb-
P660L on the localization of canalicular proteins 
could not be explained by a mere loss of myoVb motor 
function. Indeed, additional mutagenesis experiments 
showed that the disrupting effect of myoVb motor 
domain mutants on the localization of canalicular 
proteins was critically dependent on their ability to 
interact with active rab11a. Furthermore, the absence 
of intracellular clusters of BC proteins on inhibition 
of rab11a activation indicated that the mechanism 
through which myoVb mutants exerted their effects 
on the distribution of canalicular proteins involved 
active rather than inhibited rab11a function.
A recent study demonstrated that the globu-
lar tail domain of myoVb induced the clustering of 
rab11a-decorated lipid vesicles (liposomes) in a chemi-
cally defined in vitro reconstitution system by stimulat-
ing homotypic rab11-rab11 interactions.(23) Although 
this effect has thus far not been demonstrated in living 
cells, it would fit with the myoVb-Y1714–dependent 
and rab11a-dependent clustering of rab11a and asso-
ciated cargo and the appearance of clusters of vesicles 
that we observed in cells expressing myoVb-P660L 
or only the myoVb tail domain. Conceivably, the 
C-terminal tail domain of mutant myoVb, on its dis-
placement from its normal subapical location, in this 
way induced the ectopic clustering of TGN-derived 
and/or recycling endosome–derived transport vesicles 
through rab11a and thereby perturbed the correct dis-
tribution of BC proteins.
The results from this study are relevant for under-
standing the unexplained genotype-genotype cor-
relations that have been reported for PFIC6. Indeed, 
PFIC in patients without MVID has been associated 
with only biallelic missense mutations and, in contrast 
to the enteropathy in MVID, has not been associated 
with biallelic MYO5B mutations that are predicted to 
result in the loss of myoVb protein expression, such as 
nonsense or frameshift mutations.(3,12) In agreement 
with these clinical findings, we found that the expres-
sion of truncated myoVb resulting from MVID-
associated nonsense MYO5B mutations did not cause 
a canalicular protein localization defect. Together with 
the findings that myoVb as such is not required for 
the correct localization of canalicular proteins in vitro 
and in vivo, and that myoVb mutants required active 
rab11a for their disruptive effect on canalicular pro-
tein localization, this study thus provides a direct and 
simple explanation for this genotype-phenotype cor-
relation in patients with non-MVID PFIC6. It may 
also lead us to speculate that intrahepatic cholestasis 
in patients with MVID(9,14) is less likely to be caused 
by their MYO5B mutations when these involve non-
sense mutations than when these involve missense 
mutations. In support of this, a patient with MVID 
was reported with only nonsense MYO5B mutations 
and presented with cholestasis with normal GGT 
levels for 9 months, but liver biopsies showed normal 
canalicular protein localization. Cholestasis in this 
patient later spontaneously resolved.(11)
The results of this study are relevant for explor-
ing new treatment strategies, for example, for those 
patients with PFIC6 who are nonresponsive to rou-
tine treatment.(3,9) Our results suggest that the specific 
inhibition of the interaction between mutant myoVb 
and rab11a in the patients’ hepatocytes may amelio-
rate the harmful effects of the myoVb mutant on can-
alicular protein localization and thereby the PFIC in 
patients. This study thus paves the way for the discov-
ery of small molecule inhibitors of this interaction and 
the exploration of their potential beneficial effects.
Finally, the ectopic expression of the globular tail 
domain of myoVb has been widely used to implicate 
the involvement of myoVb in intracellular trafficking 
of a variety of proteins in a variety of cell types.(10,24-27) 
The results from our study, demonstrating that the 
effects of the myoVb tail domain are not necessar-
ily mimicked by the loss of myoVb expression or loss 
of rab11a activity, yet depend on their interaction 
with active rab11a, suggest that the need to recheck 
the interpretation of some of the studies using this 
myoVb mutant is warranted.
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